Abstract：
Extrahepatic malignancies are the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Of these cancers, pancreatic cancer is one of the most lethal; however, the link between NAFLD and pancreatic cancer remains unclear. Recently, various research results have been reported on the association between NAFLD and pancreatic cancer, and the results of compiling this information revealed the following. First, the prevalence of pancreatic cancer in patients with NAFLD is at 0.26%. Second, the currently evident pathogenesis includes intrapancreatic risk factors, such as: (1) non-alcoholic fatty pancreas disease, and (2) intraductal papillary mucinous neoplasm; and extrapancreatic risk factors, such as: (1) insulin resistance and adipocytokines, (2) proinflammatory cytokines, and (3) dysbiosis. Finally, metformin and sodium-glucose cotransporter 2 inhibitors may reduce the risk of pancreatic cancer in diabetes patients with NAFLD. In this review, we summarize the recent evidence on the epidemiology and mechanisms for NAFLD-related pancreatic cancer. We further discuss the impact of anti-diabetic medication on pancreatic cancer.
摘要：
肝外恶性肿瘤是非酒精性脂肪性肝病（NAFLD）患者死亡的主要原因。在这些癌症中，胰腺癌是最致命的癌症之一;然而,NAFLD与胰腺癌之间的联系尚不清楚.最近,已经报道了NAFLD与胰腺癌之间关联的各种研究结果，收集这些信息的结果揭示了以下内容。首先,NAFLD患者中胰腺癌的患病率为0.26%.第二,目前明显的发病机制包括胰腺内危险因素，如：（1）非酒精性脂肪胰腺疾病，和（2）导管内乳头状黏液性肿瘤；和胰腺外危险因素，如：（1）胰岛素抵抗和脂肪细胞因子，（2）促炎细胞因子，和（3）生态失调。最后,二甲双胍和钠-葡萄糖协同转运蛋白2抑制剂可降低糖尿病合并NAFLD患者胰腺癌的风险.在这次审查中,我们总结了NAFLD相关胰腺癌的流行病学和发病机制的最新证据.我们进一步讨论了抗糖尿病药物对胰腺癌的影响。
